Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration

Clinical and Experimental Immunology

Volumn 120, Issue 2, 2000, Pages 324-332

  Amendola, A ^a,b   Poccia, F ^a,b   Martini, F ^a   Gioia, C ^a   Galati, V ^a   Pierdominici, M ^a   Marziali, M ^a   Pandolfi, F ^a   Colizzi, V ^a,b   Piacentini, M ^a,b   Girardi, E ^a   D'Offizi, Gianpiero ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Apoptosis; CD95; HAART; IL 2; Naive cells

Indexed keywords

ANTIRETROVIRUS AGENT; FAS ANTIGEN; INDINAVIR; INTERLEUKIN 2 RECEPTOR; LAMIVUDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; STAVUDINE;

ADULT; ANTIBIOTIC THERAPY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD45; ANTIGENS, CD95; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; L-SELECTIN; LEUKOCYTES, MONONUCLEAR; MALE; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0034125406     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01223.x     Document Type: Article

References (46)

1. 1 Collier AC, Coombs RW, Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996; 334:1011-7.
2. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
3. 3 Mathez D, Bagnarelli P, Gorin I et al. Reduction in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine, zalcitabine triple therapy. Antiviral Ther 1997; 2:175-83.
4. 4 Pontesilli O, Kerkhof-Garde S, Pakker NG et al. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol Letters 1999; 66:213-7.
5. 5 Foudraine NA, Hovenkamp E, Notermans DW et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999; 13:177-84.
6. 6 Li TS, Tubiana R, Katlama C et al. Long-lasting recovery in CD4 T cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV disease. Lancet 1998; 351:1682-6.
7. 7 Bisset LR, Cone RW, Huber W et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort study. AIDS 1998; 12:2115-23.
8. 8 Roeder M. Getting to the HAART of T cell dynamics. Nat Med 1998; 4:145-6.
9. 9 Gougeon ML, Lecoeur H, Sasaki Y. Apoptosis and CD95 system in HIV disease: impact of highly active anti-retroviral therapy. Immunol Letters 1999; 66:97-103.
10. + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992; 175:331-40.
11. 11 Meyaard L, Otto SA, Jonker RR et al. Programmed death of T cells in HIV-1 infection. Science 1992; 257:217-9.
12. 12 Oyaizu N, McCloskey TW, Coronesi M et al. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 1993; 82:3392-400.
13. 13 Gougeon ML, Lecour H, Dulioust A et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons. J Immunol 1996; 156:3509-20.
14. 14 Bohler T, Walcher J, Holzl-Wenig G et al. Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. AIDS 1999; 13:779-89.
15. + and accessory cells of lymph nodes of HIV-infected persons. PNAS USA 1996; 93:11057-62.
16. 16 Badley AD, Dockrell DH, Algeciras A et al. In vitro analysis of Fas/ FasL interactions in HIV-infected patients. J Clin Invest 1998; 102:79-87.
17. 17 Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. PNAS USA 1996; 93:10405-10.
18. 18 Davey RT, Chaitt DO, Piscitelli SC et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997; 175:781-9.
19. 19 Davey RT, Chaitt DC, Albert JM et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179:849-58.
20. 20 Blanco J, Cabrera C, Jou A et al. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 1999; 13:547-55.
21. + progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996; 88:3329-35.
22. 22 Pandolfi F, Pierdominici M, Oliva A et al. Apoptosis-related mortality in vitro of mononuclear cells from patients with HIV infection correlates with disease severity and progression. J Acquir Immune Def Syndr Hum Retrovir 1995; 9:450-8.
23. 23 Kepler TB, Borrero M, Rugerio B et al. Interdependence of N nucleotide addition and recombination site choice in V(D)J rearrangement. J Immunol 1996; 157:4451-7.
24. 24 Pakker NG, Notermans DW, DeBoer RJ et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.
25. 25 Haynes B, Hale LP, Weinhold KJ et al. Analysis of the adult thymus in reconstitution of peripheral T lymphocytes in HIV-1 infection. J Clin Invest 1999; 103:453-60.
26. 26 Douek DC, McFarland RD, Reiser PH et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690-5.
27. + repertoire during antiviral therapy. Nature Med 1998; 4:215-21.
28. 28 Zanussi S, Simonelli C, Bortolin MT et al. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART+ IL-2. Clin Exp Immunol 1999; 116:486-92.
29. 29 Sousa AE, Chaves AF, Doroana M et al. Early reduction of the overexpression of CD40, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery. Clin Exp Immunol 1999; 116:307-15.
30. 30 Woods TC, Roberts BD, Butera ST et al. Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells. Blood 1997; 89:1635-41.
31. 31 Roeder M. Raju PA, Mitra DK et al. HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J Clin Invest 1997; 99:1555-64.
32. 32 Poli G, Fauci A. Role of cytokines in the pathogenesis of human immunodeficiency virus infection. In: Aggarval BB, Puri RK, eds. Human cytokines: their role in disease and therapy. Cambridge, MA: Blackwell Science, 1995:421-49.
33. 33 Aukrust P, Muller F, Lien E et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologie and immunologic treatment failure. J Infect Dis 1999; 179:74-82.
34. 34 Gurram M, Chirmule N, Wang XP et al. Increased spontaneous secretion of interleukin-6 and tumor necrosis factor alpha by peripheral blood lymphocytes of human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13:496-501.
35. 35 Levine AM, Tulpule A, Espina B et al. Low dose methotrexate, bleomicin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Cancer 1996; 78:517-26.
36. 36 David D, Bani L, Moreau JL et al. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. PNAS USA 1998; 95:11348-53.
37. 37 Chun TW, Engel D, Mizell SB et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5:651-5.
38. 38 Chun TW, Carruth L, Finzi D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-infection. Nature 1997; 387:183-8.
39. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1997; 5:512-7.
40. 40 Wong JK, Hezareh M, Gunthard HF et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
41. + T cells during primary HIV-1 infection. PNAS USA 1998; 95:8869-73.
42. + T cells using a combination of cytokines. J Exp Med 1998; 188:83-91.
43. 43 Ho DD, Neumann AU, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-infection. Nature 1995; 373:123-6.
44. 44 Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-22.
45. 45 Perelson AS, Neumann AU, Markowitz M et al. HIV dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.
46. 46 Welte K, Gabrilove J, Bronchud MH et al. Filgrastim (R-metHuG-CSF): the first 10 years. Blood 1988; 6:1907-29.